Company profile
PharmaCyte Biotech, Inc.
NASDAQ: PMCB · Healthcare · Biotechnology
#1161 of 1,418 Healthcare companies by revenue
EA Score
——FH —DQ 55GM —SS 36
v0.1 · 25/100 weight · pillars only
↑ return on assets, balance-sheet leverage · ↓ Piotroski F, workforce scale
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
$30.7M
Employees
2
as of 2026-08-23
Market cap
$5.7M
as of 2026-08-23
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02025
Net income$30.7M$30.7M2025
Operating income-$4.4M-$4.4M2025
Total assets$55.2M$55.2M2025
Liabilities$3.3M$3.3M2025
Equity$51.9M$51.9M2025
Revenue trend
FY2018 – FY2025 · USD
FY18
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is PharmaCyte Biotech, Inc.’s revenue?
PharmaCyte Biotech, Inc. booked $0 in FY2025 revenue — among the slowest-growing Healthcare companies we track, at a Infinity% net margin.
Peers · Healthcare
Exicure, Inc.31DSweet Earth Holdings Corporation22DProcessa Pharmaceuticals, Inc.39DENDRA Life Sciences Inc.25DWEED, Inc.19DMustang Bio, Inc.41DNeighbors
Clark →Key facts
CEOJoshua N. Silverman
SectorHealthcare
IndustryBiotechnology
HeadquartersLas Vegas, NV
ExchangeNASDAQ: PMCB
Employees2
IPO date2013-01-02
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.